Journal
BIOTECHNOLOGY LETTERS
Volume 36, Issue 10, Pages 2143-2153Publisher
SPRINGER
DOI: 10.1007/s10529-014-1585-3
Keywords
Critical-sized chondral defect; Mesenchymal stromal cells; Polylactide:polyglycolic acid preclinical animal model; Regenerative medicine; Scaffold; Second-look arthroscopy; Sheep
Categories
Funding
- Ministerio de Economia y Competitividad [IPT-300000-2010-0017]
- Ministerio de Ciencia e Innovacion [PSE-010000-2007-4//PSE-010000-2008-4, BIO2008-01985]
- Programa de suport a grups d'investigacio DGR/DIUE [2009SGR1038]
- Spanish Cell Therapy Network (TerCel)
- European Regional Development Fund (ERDF), within the National Plan for Scientific Research, Development and Innovation
Ask authors/readers for more resources
Clinical translation of emerging technologies aiming at cartilage resurfacing is hindered by neither the appropriate scaffold design nor the optimal cell source having been defined. Here, critical-sized, chondral-only focal defects were created in sheep and treated with clinical-grade, co-polymeric poly-lactide:polyglycolic acid scaffolds either alone or seeded with 3.3 x 10(6) +/- A 0.4 x 10(6) autologous bone marrow-derived mesenchymal stromal cells and studied over 12 month follow-up. An untreated group was included for comparison. Second-look arthroscopy performed at 4 months post-treatment evidenced the generation of neocartilage of better quality in those defects treated with cells. However, macroscopic scores in the cell-treated group declined significantly from 7.5 +/- A 2.3 at 4 months to 3.1 +/- A 2.6 (p = 0.0098) at 12 months post-treatment, whereas the other two experimental groups remained unaltered during 4-12 month post-treatment. The effectiveness of the cell-based approach proposed in this study is thus restricted to between months 1 and 4 post-treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available